Where I disagree is neither on these great aims nor on every patient’s wish to have more rapid access, at Community level, to medicinal products containing new, safer and more effective active substances, but on certain specific details of the regulation, as demonstrated in the way I voted on this matter.
Les divergences ne concernent pas ces grands objectifs, ni le souhait de tous les patients de disposer plus rapidement, au niveau communautaire, de médicaments contenant de nouvelles substances actives, plus sûrs et efficaces. Elles concernent certains détails concrets de la réglementation, comme le montre mon vote.